Last reviewed · How we verify

Generic Azelaic Acid Foam

Actavis Inc. · Phase 3 active Small molecule

Azelaic acid reduces inflammation and bacterial growth in the skin by inhibiting mitochondrial enzymes and reducing reactive oxygen species production.

Azelaic acid reduces inflammation and bacterial growth in the skin by inhibiting mitochondrial enzymes and reducing reactive oxygen species production. Used for Acne vulgaris, Rosacea.

At a glance

Generic nameGeneric Azelaic Acid Foam
SponsorActavis Inc.
Drug classTopical antimicrobial and anti-inflammatory agent
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Azelaic acid exerts antimicrobial effects against Cutibacterium acnes and has anti-inflammatory properties that reduce erythema and papules. It also normalizes keratinization and reduces the production of inflammatory mediators, making it effective for treating acne and rosacea. The foam formulation enhances skin penetration and patient tolerability.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: